Vertas Group is celebrating a major milestone in its partnership with Cancer Research UK, having raised more than £100,000 since 2017. This achievement reflects seven years of dedication, teamwork, and community spirit, supporting life-saving research and making a real difference.
In 2025 alone, the Group raised over £25,000, with the return of the popular Exec Experiences initiative contributing more than £19,000 (including Gift Aid) to the total this year.
Led by each director, initiatives included the Great Birmingham Run, a 53km coastal walk in Suffolk from Lowestoft to Aldeburgh, and the Whole Hog challenge in Woodbridge. But the team didn’t stop there. Under the leadership of Kate Innes, Group Chief People Officer at Vertas Group, colleagues abseiled 90 feet from Miller Dale Viaduct in Derbyshire. They also took on a ‘Coast to Coast’ cycling challenge, led by Ian Surtees, Group Chief Executive Officer of Vertas Group and Duncan Johnson, Non-Executive Chair of Vertas Group. The team cycled 223km from Whitehaven to Tynemouth, climbing an impressive 10,000 feet in elevation.
Sharing his gratitude to those involved, Ian Surtees, MBA FIoD, said: “I’m incredibly proud of our colleagues for their passion and determination. Reaching £100,000 is a testament to what we can achieve together for such an important cause. This milestone reflects not only our commitment to Cancer Research UK but also the strength of our culture, one built on teamwork, resilience, and making a positive impact in the communities we serve.”
Other highlights of this year’s efforts include their annual Vertas Group Golf Day, the Making the Difference Awards raffle and auction, and their annual Bake Sale. Each event has inspired colleagues across the Group to get involved and make a difference. Together, these achievements demonstrate Vertas Group’s unwavering commitment to social responsibility and community impact.
Vertas Group extends heartfelt thanks to every colleague who contributed to this incredible journey. With a new fundraising initiative launching in the new year, the Group remains committed to making an even greater impact for Cancer Research UK.
